Tags

Type your tag names separated by a space and hit enter

Vaginal microbicides.
Adolesc Med Clin. 2006 Oct; 17(3):673-85; abstract xi.AM

Abstract

This article reviews the current status of microbicide development and challenges faced in developing safe and effective compounds. The ever growing HIV pandemic, lack of effective vaccines against HIV and other sexually transmitted infections, concern about the vulnerability of women, and difficulty in condom negotiation are factors that drive the development of topical microbicides as a prophylactic method for women. The ideal microbicide needs to be safe and highly effective and not increase viral resistance or cause disruption of host defenses. Advances in the understanding of HIV transmission and the role of other sexually transmitted infections have allowed progress in development of microbicide candidates as clinical trials of potential agents are awaited.

Links

Publisher Full Text

Authors+Show Affiliations

O'Brien RF
Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, Tufts University School of Medicine, The Floating Hospital for Children at Tufts-New England Medical Center, Boston, MA 02111, USA. robrien@tufts-nemc.org

MeSH

Anti-Infective Agents, LocalAntiviral AgentsFemaleHIV InfectionsHumansSpermatocidal AgentsVaginal Creams, Foams, and Jellies

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17030285

Citation

O'Brien, Rebecca Flynn. "Vaginal Microbicides." Adolescent Medicine Clinics, vol. 17, no. 3, 2006, pp. 673-85; abstract xi.
O'Brien RF. Vaginal microbicides. Adolesc Med Clin. 2006;17(3):673-85; abstract xi.
O'Brien, R. F. (2006). Vaginal microbicides. Adolescent Medicine Clinics, 17(3), 673-85; abstract xi.
O'Brien RF. Vaginal Microbicides. Adolesc Med Clin. 2006;17(3):673-85; abstract xi. PubMed PMID: 17030285.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaginal microbicides. A1 - O'Brien,Rebecca Flynn, PY - 2006/10/13/pubmed PY - 2007/1/31/medline PY - 2006/10/13/entrez SP - 673-85; abstract xi JF - Adolescent medicine clinics JO - Adolesc Med Clin VL - 17 IS - 3 N2 - This article reviews the current status of microbicide development and challenges faced in developing safe and effective compounds. The ever growing HIV pandemic, lack of effective vaccines against HIV and other sexually transmitted infections, concern about the vulnerability of women, and difficulty in condom negotiation are factors that drive the development of topical microbicides as a prophylactic method for women. The ideal microbicide needs to be safe and highly effective and not increase viral resistance or cause disruption of host defenses. Advances in the understanding of HIV transmission and the role of other sexually transmitted infections have allowed progress in development of microbicide candidates as clinical trials of potential agents are awaited. SN - 1547-3368 UR - https://www.unboundmedicine.com/medline/citation/17030285/Vaginal_microbicides_ L2 - http://journals.elsevierhealth.com/retrieve/pii/S1547-3368(06)00029-5 DB - PRIME DP - Unbound Medicine ER -